百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop

動脈網

04-03

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百濟神州決定停止開發其靶向TIGIT的藥物ociperlimab，這是該藥物類別遭遇的又一次挫折。The Nasdaq-listed company...

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524521263"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524521263\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524521263?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-04-03 21:49","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2524521263","market":"sh","top_or_hot":-1,"title":"百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop","media":"動脈網","content":"<div>\n<p>BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百濟神州決定停止開發其靶向TIGIT的藥物ociperlimab，這是該藥物類別遭遇的又一次挫折。The Nasdaq-listed company...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-04-03 21:49</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百濟神州決定停止開發其靶向TIGIT的藥物ociperlimab，這是該藥物類別遭遇的又一次挫折。The Nasdaq-listed company...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b","article_id":"2524521263","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2524521263","pubTimestamp":1743688140,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百濟神州決定停止開發其靶向TIGIT的藥物ociperlimab，這是該藥物類別遭遇的又一次挫折。TIGITTIGITin particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody特別是被證明是藥物開發人員的一個棘手目標，而百濟神州的決定是在默克公司放棄其抗TIGIT抗體開發的幾個月後做出的。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"BeiGene drops TIGIT antibody after failed lung cancer trial BeiGene abandons TIGIT antibody after lung cancer flop","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":0.9,"ONC":0.9},"content_text":"BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百濟神州決定停止開發其靶向TIGIT的藥物ociperlimab，這是該藥物類別遭遇的又一次挫折。The Nasdaq-listed company – which is planning to rebrand as BeOne Medicines – said that the decision follows a futility analysis of the phase 3 AdvanTIG-302 trial of ociperlimab (BGB-A1217) by the study's independent data monitoring committee which indicated the drug was unlikely to show an improvement in overall survival..這家在納斯達克上市的公司（計劃更名為BeOne Medicines）表示，這一決定是基於獨立數據監察委員會對ociperlimab（BGB-A1217）三期臨牀試驗AdvanTIG-302進行的無效性分析，結果顯示該藥物不太可能顯示出總生存期的改善。AdvanTIG-302 was pitting the combination of ociperlimab with BeiGene's PD-1 inhibitor Tevimbra (tislelizumab) against MSD's $29.5 billion-a-year PD-1 inhibitor Keytruda (pembrolizumab) in previously untreated, advanced PD-L1-positive non-small cell lung cancer (NSCLC).AdvanTIG-302研究正在將ociperlimab與百濟神州的PD-1抑制劑替雷利珠單抗（Tevimbra）聯合使用，與默沙東年銷售額達295億美元的PD-1抑制劑Keytruda（帕博利珠單抗）進行對比，用於既往未經治療、PD-L1陽性的晚期非小細胞肺癌（NSCLC）。'We evaluate our clinical programmes to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritising others,' said Mark Lanasa, BeiGene's chief medical officer.“我們評估我們的臨牀項目，將資源集中在最有希望的、具有臨牀差異化的候選藥物上，同時經過深思熟慮後降低其他項目的優先級，”百濟神州首席醫學官Mark Lanasa表示。'Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide.'“我們的承諾依然堅定不移：發現和開發更實惠、更易獲得的創新治療方法，惠及全球癌症患者。”The decision follows negative results in other ociperlimab trials, so isn't wholly unexpected, but is another example of the difficulties companies are facing in developing additional checkpoint inhibitors that work alongside the PD-1/PD-L1 inhibitors which currently dominate the cancer immunotherapy category..該決定是在其他 ociperlimab 試驗結果不佳之後做出的，因此並不完全出乎意料，但這也是公司正在面臨的開發與目前主導癌症免疫治療類別的 PD-1/PD-L1 抑制劑協同工作的額外檢查點抑制劑的困難的另一個例子。TIGITTIGITin particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody特別是被證明是藥物開發人員的一個棘手目標，而百濟神州的決定是在默克公司放棄其抗TIGIT抗體開發的幾個月後做出的。vibostolimab振動棒單抗after a series of disappointing trial results, along with its anti-LAG-3 candidate favezelimab.在一系列令人失望的試驗結果之後，其抗LAG-3候選藥物favezelimab也表現不佳。Last year, Bristol Myers Squibb also returned rights to去年，百時美施貴寶公司也歸還了權利給AGEN1777AGEN1777, a TIGITxCD96 bispecific antibody partnered with Agenus in a $1.56 billion deal, saying the intention was to 'realign' its product pipeline.，一種與Agenus合作的價值15.6億美元的TIGITxCD96雙特異性抗體，稱其目的是“重新調整”其產品管線。Other TIGIT drugs from Roche and Gilead/Arcus meanwhile have also suffered setbacks in first-line NSCLC, with Roche now focusing its efforts with tiragolumab on liver and oesophageal cancers after the drug seemed to worsen outcomes in an NSCLC study.與此同時，羅氏和吉利德/Arcus的其他TIGIT藥物在一線非小細胞肺癌（NSCLC）中也遭遇了挫折，此前一項NSCLC研究顯示tiragolumab似乎惡化了治療結果，因此羅氏現在將其研發重點轉向肝癌和食管癌。After one phase 3 trial failure, Gilead/Arcus still has one study remaining for its domvanalimab antibody in this setting, alongside a phase 3 trial in upper gastrointestinal cancer, with active programmes in first-line NSCLC also ongoing for iTeos/GSK's在一項三期試驗失敗後，吉利德/Arcus公司在此適應症上仍有另一項關於domvanalimab抗體的研究正在進行中，同時還在上消化道癌症中進行着一項三期試驗，而iTeos/GSK在一線非小細胞肺癌的項目也在持續推進。belrestotug貝爾雷斯特圖格antibody and AstraZeneca's TIGITxPD-1 bispecific antibody抗體和阿斯利康的TIGITxPD-1雙特異性抗體rilvegostomig里爾韋戈斯托米吉.。BeiGene said it would present the results from AdvanTIG-302 at a future medical congress 'to help advance science and the understanding of anti-TIGIT activity.'百濟神州表示，將在未來的醫學大會上展示AdvanTIG-302的研究結果，“以幫助推動科學和對anti-TIGIT活性的理解。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}